What Peptides Do Women Use for Anti-Aging?

Why Peptides Have Gained Traction in Women's Anti-Aging

Peptides are short chains of amino acids, typically 2 to 50 residues, that act as signaling molecules in human tissue. Their appeal in anti-aging medicine comes from their specificity: unlike broad hormonal interventions, peptides can target narrow pathways such as collagen synthesis, growth hormone release, or mitochondrial repair. The female anti-aging market has grown rapidly alongside telehealth platforms that now offer peptide consultations directly to patients.

The Biological Basis

Aging skin loses roughly 1% of its collagen per year after age 30, according to data published in the American Journal of Pathology [1]. Estrogen decline during perimenopause accelerates this loss. Peptides that signal fibroblasts to produce collagen, or that reduce oxidative damage at the mitochondrial level, address mechanisms that standard topical retinoids and sunscreens do not fully cover.

Regulatory Reality

No peptide is FDA-approved specifically for "anti-aging." Bremelanotide (PT-141) holds FDA approval for hypoactive sexual desire disorder in premenopausal women [2], and tesamorelin is approved for HIV-associated lipodystrophy [3]. Every other peptide discussed in this article is used off-label or obtained through compounding pharmacies. The Endocrine Society's 2019 guideline on growth hormone therapy explicitly notes that GH or GH secretagogue use for age-related decline in otherwise healthy adults is not supported by current evidence [4].

GHK-Cu: The Copper Peptide With the Deepest Skin Data

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that declines with age. Plasma levels drop from about 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 [5]. It signals through multiple pathways, including upregulation of collagen I, collagen III, elastin, and glycosaminoglycans.

Topical Applications

A 2018 controlled trial published in the Journal of Aging Research and Clinical Practice found that women applying a GHK-Cu serum twice daily for 12 weeks saw a statistically significant improvement in skin density and reduction in fine wrinkle depth compared to vehicle control [5]. Dr. Loren Pickart, the biochemist who first isolated GHK-Cu, has stated: "GHK-Cu remodels skin at the gene expression level, activating over 4,000 genes associated with tissue repair and anti-inflammation" [5].

Injectable and Subcutaneous Use

Some anti-aging clinics prescribe subcutaneous GHK-Cu injections at doses of 1 to 2 mg per day. Peer-reviewed injectable data in humans is limited. Animal wound-healing models show accelerated closure and reduced scarring [5], but large human trials for cosmetic anti-aging have not been completed.

Who It Suits Best

GHK-Cu is generally well-tolerated topically. Women seeking measurable improvements in skin texture without systemic hormonal effects often start here. The compound does not raise IGF-1 or affect the hypothalamic-pituitary axis.

Oral Collagen Peptides: The Most Studied Option

Hydrolyzed collagen peptides (types I and III, typically derived from bovine or marine sources) are the most widely researched peptide supplement in dermatology.

Clinical Evidence

A double-blind, placebo-controlled trial by Proksch et al. (N=69) showed that 2.5 g/day of specific collagen peptides improved skin elasticity by 7% after 8 weeks in women aged 35 to 55, with effects persisting 4 weeks after discontinuation [6]. A 2019 systematic review and meta-analysis in the Journal of Drugs in Dermatology (11 studies, N=805) concluded that oral collagen supplementation significantly improved skin hydration, elasticity, and wrinkle outcomes versus placebo [7].

Dosing Patterns

Most positive trials used doses between 2.5 g and 10 g daily. The bioavailable peptide fragments (particularly prolyl-hydroxyproline and hydroxyprolyl-glycine) reach the dermis and signal fibroblast activity directly [6].

Limitations

Collagen peptides do not address deeper aging mechanisms like mitochondrial dysfunction, telomere attrition, or hormonal decline. They are a surface-layer intervention. Women looking for systemic anti-aging effects often combine collagen peptides with other compounds.

CJC-1295 and Ipamorelin: Growth Hormone Secretagogues

This combination is the most popular injectable peptide protocol in the anti-aging space. CJC-1295 is a modified growth hormone-releasing hormone (GHRH) analog, and ipamorelin is a selective growth hormone secretagogue receptor agonist. Together, they stimulate pulsatile GH release without significantly raising cortisol or prolactin.

What the Data Shows

A pharmacokinetic study of CJC-1295 (with drug affinity complex) showed that a single 30 mcg/kg subcutaneous dose increased mean GH levels 2- to 10-fold for 6 days and raised IGF-1 levels 1.5- to 3-fold for 9 to 11 days [8]. Ipamorelin, studied in a Phase II trial for postoperative ileus recovery (N=114), demonstrated dose-dependent GH release with minimal side effects at doses up to 0.06 mg/kg [9].

No published randomized trial has evaluated the CJC-1295/ipamorelin combination specifically for cosmetic anti-aging in women. The evidence is extrapolated from GH physiology and individual compound data.

Typical Protocols

Anti-aging clinics commonly prescribe 100 to 300 mcg of each peptide, injected subcutaneously before bedtime 5 nights per week, cycling 8 weeks on and 4 weeks off. The rationale for nighttime dosing is to amplify the natural nocturnal GH pulse.

Risks and Monitoring

The Endocrine Society warns that sustained GH elevation may increase insulin resistance, fluid retention, joint pain, and theoretical cancer risk via IGF-1 pathway activation [4]. Dr. Anne Cappola of the University of Pennsylvania wrote in Annals of Internal Medicine: "The evidence does not support GH or GH secretagogue use for age-related changes in body composition in healthy older adults" [10]. Women considering these peptides should have baseline and serial IGF-1, fasting glucose, and HbA1c monitoring.

BPC-157: The Tissue Repair Peptide

Body protection compound-157 is a 15-amino-acid peptide derived from a fragment of human gastric juice. It has generated interest for its effects on wound healing, tendon repair, and gut mucosal integrity.

Preclinical Promise

Over 100 animal studies show BPC-157 accelerating healing in tendons, ligaments, muscle, bone, and intestinal mucosa [11]. Mechanisms include upregulation of growth hormone receptor expression, nitric oxide synthesis, and VEGF-mediated angiogenesis [11].

Human Evidence Gap

Zero published randomized controlled trials exist in humans as of mid-2026. Women using BPC-157 for anti-aging purposes (typically 250 to 500 mcg subcutaneously per day) are relying entirely on animal models and anecdotal reports. The FDA issued a warning letter in 2023 regarding BPC-157 marketing as an unapproved drug [12].

Safety Considerations

Animal toxicology data shows a favorable safety profile at standard doses, but long-term human safety data does not exist. Women who are pregnant, breastfeeding, or have active malignancies should avoid BPC-157 given the absence of safety data in these populations.

Epithalon: Telomere-Targeted Peptide

Epithalon (also spelled epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled after epithalamin, a peptide extracted from the pineal gland. Its proposed mechanism involves activation of telomerase, the enzyme that maintains telomere length.

The Khavinson Research

Most epithalon research originates from Vladimir Khavinson's laboratory in St. Petersburg. A 2003 study published in the Bulletin of Experimental Biology and Medicine reported that epithalon activated telomerase in human somatic cells and increased the maximum number of cell divisions beyond the Hayflick limit [13]. A separate observational study followed 266 elderly subjects over 6 years and reported that those receiving epithalamin-containing preparations had a 1.6- to 1.8-fold reduction in mortality compared to controls [14].

Limitations of the Evidence

These studies have not been independently replicated outside Khavinson's group. Western peer-reviewed journals have published limited data on epithalon. Sample sizes are small, blinding procedures are inconsistently described, and most positive results come from a single research institution.

Current Use

Women using epithalon typically inject 5 to 10 mg subcutaneously daily for 10 to 20 days, repeated every 4 to 6 months. Without independent replication, this remains an experimental protocol.

SS-31 (Elamipretide): Mitochondrial Anti-Aging

SS-31 is a mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane, stabilizing cardiolipin and reducing reactive oxygen species production.

Clinical Trial Progress

The TAZPOWER trial evaluated elamipretide in patients with Barth syndrome (a mitochondrial cardiomyopathy) and showed improvements in 6-minute walk distance [15]. Stealth BioTherapeutics has also studied elamipretide in age-related macular degeneration (the ReCLAIM trials), with mixed results on primary endpoints but signals of retinal structural preservation [16].

Relevance for Women

Mitochondrial decline is a core driver of aging across organ systems. SS-31 represents a mechanistically distinct approach compared to collagen or GH peptides. It is not commercially available outside clinical trials as of mid-2026, though compounding pharmacies have offered analogs.

How to Evaluate a Peptide Protocol

Not all peptide programs are equal. Women considering anti-aging peptides should apply a structured evaluation before starting any protocol.

Check the Evidence Tier

Collagen peptides have multiple RCTs. GHK-Cu has controlled human skin studies. CJC-1295 and ipamorelin have pharmacokinetic data but no anti-aging RCTs. BPC-157 and epithalon have only animal or single-group studies. Match your risk tolerance to the evidence level.

Demand Lab Monitoring

Any protocol involving GH secretagogues requires baseline and periodic IGF-1, fasting insulin, fasting glucose, HbA1c, and a lipid panel. The American Association of Clinical Endocrinology recommends these markers for any patient on GH-axis therapies [17].

Verify Compounding Pharmacy Standards

Injectable peptides should come from a 503B outsourcing facility registered with the FDA, not an overseas research chemical supplier. Contamination, mislabeling, and under-dosing are documented risks with unregulated peptide sources [12].

Peptides vs. Established Anti-Aging Interventions

Peptides do not replace interventions with decades of evidence. Tretinoin (topical retinoid) has over 30 years of RCT data showing reversal of photoaging [18]. Broad-spectrum sunscreen prevents 80% of visible skin aging. Hormone replacement therapy in menopausal women addresses the estrogen decline that drives accelerated collagen loss, bone density reduction, and cardiovascular changes, and the 2022 Menopause Society position statement supports HRT initiation within 10 years of menopause onset for symptomatic women [19].

Peptides may complement these interventions. They should not replace them.

Safety Across Peptide Categories

| Peptide | Route | Common Dose Range | Human RCT Data | FDA Status | |---|---|---|---|---| | Collagen peptides | Oral | 2.5-10 g/day | Yes (multiple) | GRAS supplement | | GHK-Cu | Topical/SC | 1-2 mg/day (SC) | Limited | Not approved | | CJC-1295/Ipamorelin | SC | 100-300 mcg each | PK only | Not approved | | BPC-157 | SC/Oral | 250-500 mcg/day | None | Not approved | | Epithalon | SC | 5-10 mg/day x 10-20 days | Single-group only | Not approved | | SS-31 | SC | Trial doses vary | Phase II/III (disease) | Investigational |

Women with hormone-sensitive conditions (breast cancer history, active endometriosis, or estrogen receptor-positive fibroids) should discuss any peptide protocol with their oncologist or gynecologist before initiation, particularly GH secretagogues that raise IGF-1.